Propanc Biopharma, Inc. announced an update on pancreatic cancer research, highlighting the high unmet need for effective treatments due to the low survival rates. Their lead candidate, PRP, has shown promising results in preclinical studies, with potential to inhibit tumor growth and enhance sensitivity to chemotherapy. The FDA granted Orphan Drug Designation to PRP in 2017. Propanc plans to initiate Phase I/II clinical trials in 2026. The global pancreatic cancer treatment market is projected to grow significantly, with Propanc targeting a market opportunity of $6.93 billion by 2030. Despite financial challenges, Propanc is focused on advancing their innovative treatment option for pancreatic cancer.

Read more at GlobeNewswire: Propanc Biopharma Explains How PRP Could Impact Pancreatic